{"entity":{"id":"geron","kind":"company","name":"Geron Corporation","aka":["Geron"],"tldr":"Geron is the Californian company behind imetelstat, the first telomerase inhibitor to reach approval, cleared by the FDA in 2024 for lower-risk myelodysplastic syndromes with transfusion-dependent anaemia.","summary":"Geron Corporation, based in Foster City, California, spent three decades on telomerase biology before its oligonucleotide telomerase inhibitor imetelstat (Rytelo) was approved by the FDA in June 2024 for adults with lower-risk myelodysplastic syndromes and transfusion-dependent anaemia who had failed or were ineligible for erythropoiesis-stimulating agents, on the IMerge trial. Imetelstat is also in a phase 3 trial in relapsed or refractory myelofibrosis. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Geron_Corporation","links":[{"label":"Official website","url":"https://www.geron.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["mds","myeloproliferative-neoplasms"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["imetelstat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05583552","impactmf"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Foster City, CA","country":"US","companyType":"biotech","website":"https://www.geron.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/geron/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/"}],"trial":[{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/"},{"id":"impactmf","kind":"trial","name":"IMpactMF","route":"/trials/impactmf/"},{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","route":"/trials/nct05583552/"}]}}